ChrysalisBioTherapeutics, Inc. is a privately held biopharmaceutical company developing regenerative drugs that mimic the body’s natural signals to activate endothelial progenitor cells and stem cells to stimulate tissue repair and restore normal tissue function. Chrysalis BioTherapeutics was incorporated in Delaware in 2012 to develop innovative peptide therapeutics to save lives and improve life’s quality.
Chrysalis’ lead drug candidate, TP508, was initially developed to accelerate healing of dermal and musculoskeletal injuries. TP508 proved to be especially effective in promoting healing of diabetic foot ulcers in early human clinical trials and is under development as a treatment for mass casualty injuries and unmet clinical needs. Chrysalis has demonstrated that TP508 mitigates effects of radiation exposure and is collaborating with US government agencies to develop TP508 as a nuclear countermeasure to increase survival and combat acute and delayed radiation syndromes. In addition, the company is developing TP508 to prevent damaging effects of trauma and radiation therapy on the brain and other tissues.